Sagacious IP Blogs

  What is New in WIPO’s ST.26 Sequence Listing Standard All patent applications specifying nucleotide or amino acid sequences must include a sequence listing. The  World Intellectual Property Organization  (WIPO) has set forth international standards for preparing sequence listings, and failure to comply with these guidelines may result in the rejection of the patent application. WIPO recently introduced the latest sequence listing standard, ST26, which aims to enhance data searching and transfer for patent offices, inventors, and applicants alike. This article explores ST26 and delves into its features, benefits, drawbacks of the previous standard (ST25), and more.

  Understanding Sequence Listing in Patent Application and Scope of IP Protection Biotechnology patent applications often involve nucleotide and amino acid sequences that require proper disclosure to obtain IP protection. The sequence listing is a standardized document essential at patent offices worldwide to provide a detailed description of these sequences. Moreover, patent applicants should ensure that their sequence listings comply with all applicable guidelines and requirements. This is done to avoid potential loss of IP rights. This article will discuss the meaning and need for sequence listing in patent application.

  The Art of ST.26 Sequence Listing Preparation: Best Practices for Accuracy and Compliance Sequence listings are an essential part of biotech patent applications. They list nucleotide and/or amino acid sequences associated with the invention. These sequence listings assist patent offices in evaluating the novelty and non-obviousness of inventions. Thus, their accuracy, completeness, and compliance with the latest sequence listing standard are critical to the success of the patent application. In this article, we will discuss the best practices for ST26-compliant sequence listing preparation. By following these best practices, you can increase your chances of success in obtaining a patent for your invention.

  ST.25 vs ST.26: A Comparative Analysis of Patent Sequence Listing Standards    The world of intellectual property is vast and complex. Various standards and guidelines ensure to document these inventions and innovations correctly. Specifically, in the realm of biotechnology and genetic engineering, patent sequence listings play a crucial role in applications as they provide a detailed representation of the nucleotide and amino acid sequences that make up an invention. Over the years, several standards have been established to govern the formatting and submission of these patent sequence listings. Notably, two of the most significant patent sequence listing standards in this area are ST.25 and ST.26. In this article, we will delve into the differences between these two standards, exploring their respective strengths and weaknesses for patent sequence listing preparation. 

 How TSLC’s Sequence Listing Service Helped an IAM 500 Law Firm Streamline Patent Operations  Patent applications in the biotechnology domain require a detailed sequence listing, which is a critical part of the patent application process. These listings are essential for determining the scope of a patent and ensuring its compliance with international patent filing requirements. However, creating and maintaining sequence listings can be a time-consuming, resource-intensive, and challenging task, and not all businesses have in-house capabilities to manage the same. Thus, it is often recommended to avail the sequence listing service of an external partner expert in the space. This case study discusses how The Sequence Listing Company (TSLC) helped a top-tier IAM 500 law firm in managing the sequence listings for its clients’ patent applications. You will read about the solution provided by TSLC and the impact it created. But first, let us delve into the challenges in this case st...